Allelica on Wednesday announced the launch of an ancestry-specific polygenic risk score (PRS) analysis as a laboratory-developed test (LDT) for coronary artery disease, breast cancer, prostate cancer, type 2 diabetes, and Alzheimer's disease.
The firm said its tests are made possible through a partnership with Clinical Enterprise, a CLIA-certified, CAP-accredited laboratory located in Framingham, MA.
Ordered by physicians, the tests use a patient's saliva for genotyping analysis conducted by Clinical Enterprise, leveraging genome-wide microarray technology.
The output of the microarray analysis is input into the Allelica platform, which applies proprietary algorithms to calculate an ancestry-specific PRS and generate clinical-grade reports.
Allelica added that Brigham and Women's Hospital is among the first healthcare facilities to make the analysis available through its Preventive Genomics Clinic, where PRS is being used along with comprehensive whole-genome sequencing to provide patients with personal disease risk factors.
